SCHEMBL18367704

SCHEMBL18367704

Cn1ccnc1-c1cccc(C(C)(C)C)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.51
TMEM97 Q5BJF2 1/20 0.44
SIGMAR1 Q99720 1/20 0.44
OPRD1 P41143 3/20 0.43
OPRM1 P35372 1/20 0.43
OPRK1 P41145 1/20 0.43
NMT1 P30419 1/20 0.43
KMT2A Q03164 2/20 0.41
RIPK2 O43353 1/20 0.40
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
PRKDC P78527 1/20 0.38
NTRK1 P04629 1/20 0.38
BRD4 O60885 1/20 0.38
MEN1 O00255 1/20 0.38
ACLY P53396 1/20 0.38
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
CCNC P24863 1/20 0.36
CDK8 P49336 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12832618 0.86 NPC1 (0.47) NMT1BRD4
SCHEMBL14412223 0.84 NMT1 (0.52) NMT1RIPK2PRKDCNTRK1BRD4
SCHEMBL12759448 0.81 TGFBR1 (0.48) NMT1KMT2ARIPK2PRKDCNTRK1
SCHEMBL17264894 0.80 NMT1 (0.52) NMT1RIPK2PRKDCNTRK1BRD4
SCHEMBL10176272 0.80 KIF11 (0.47) KIF11SIGMAR1KMT2AMEN1HDAC4
SCHEMBL12581539 0.78 NMT1 (0.41) NMT1RIPK2PRKDCNTRK1BRD4
SCHEMBL13994035 0.77 RIPK2 (0.48) NMT1RIPK2PRKDCNTRK1BRD4
SCHEMBL12320076 0.77 KDR (0.47) NMT1KMT2ARIPK2PRKDCNTRK1
SCHEMBL3488664 0.77 IDO1 (0.49) NMT1KMT2ARIPK2BRD4MEN1
SCHEMBL3489826 0.77 NMT1 (0.47) NMT1KMT2ARIPK2PRKDCNTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827662-B2 Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (US) 2023-11-28 US disclosed
US-11827662-B2 Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (US) 2023-11-28 US disclosed
US-11325930-B2 Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (US) 2022-05-10 US disclosed
US-20210147454-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2021-05-20 US disclosed
US-10947259-B2 Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (US) 2021-03-16 US disclosed
US-20210061831-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2021-03-04 US disclosed
US-20200392170-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2020-12-17 US disclosed
US-10316017-B2 COT modulators and methods of use thereof GILEAD SCIENCES, INC. (US) 2019-06-11 US disclosed
US-20170362201-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2017-12-21 US disclosed
US-20170362201-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2017-12-21 US disclosed
US-9815818-B2 Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (US) 2017-11-14 US disclosed
US-9815818-B2 Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (US) 2017-11-14 US disclosed
US-20170008873-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2017-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362201-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS KIF11 3487/4885TMEM97 1558/4885SIGMAR1 978/4885
US-11325930-B2 Cot modulators and methods of use thereof BRDT, THRB, HCCS KIF11 3487/4885TMEM97 1558/4885SIGMAR1 978/4885
US-20200392170-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS KIF11 3487/4885TMEM97 1558/4885SIGMAR1 978/4885
US-10316017-B2 COT modulators and methods of use thereof BRDT, THRB, HCCS KIF11 3487/4885TMEM97 1558/4885SIGMAR1 978/4885
US-10947259-B2 Cot modulators and methods of use thereof BRDT, THRB, HCCS KIF11 3487/4885TMEM97 1558/4885SIGMAR1 978/4885
US-20210147454-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS KIF11 3487/4885TMEM97 1558/4885SIGMAR1 978/4885
US-20210061831-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS KIF11 3487/4885TMEM97 1558/4885SIGMAR1 978/4885
US-11827662-B2 Cot modulators and methods of use thereof BRDT, THRB, HCCS KIF11 3487/4885TMEM97 1558/4885SIGMAR1 978/4885
US-20170008873-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS KIF11 3487/4885TMEM97 1558/4885SIGMAR1 978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.